Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More
Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More
Psyched：國防部。”s ****試驗、Cybin's psilocybin、代謝障礙、改革更新等
Defense Dept. Funds Ketamine Study For PTSD Treatment
國防部資助用於創傷後應激障礙治療的****研究
A DOD Health Agency-funded adaptive platform trial for alternative treatments for PTSD will test SLS-002 on some 600 active-duty service members and veterans. The intranasal racemic ketamine was developed by biotech company Seelos Therapeutics (NASDAQ:SEEL).
一項由國防部衛生署資助的創傷後應激障礙替代療法適應平台試驗將在大約 600 名現役軍人和退伍軍人身上測試 SLS-002。鼻內消旋****由生物技術公司Seelos Therapeutics（納斯達克股票代碼：SEEL）開發。
The new Phase 2 study will use an adaptive platform trial design involving a 30-day screening period, a 12-week treatment period, and a four-week follow-up to assess safety, tolerability and efficacy of multiple doses of SLS-002 paired with therapy. Read more HERE.
新的2期研究將使用自適應平台試驗設計，包括30天的篩查期、12周的治療期和四周的隨訪，以評估多劑量 SLS-002 與治療相結合的安全性、耐受性和有效性。在這裏閱讀更多。
Cybin's Novel Psilocybin Topline Data
Cybin 的新型 psilocybin 頭條數據
Next-generation psychedelics biotech Cybin Inc...
下一代迷幻藥...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。